Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-56278 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06480552Phase 1Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2024
- Primary completion
- May 2029
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of TEV-56278 in solid tumor, melanoma and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Incidence of Adverse Events with CTCAE Grade>=3 up to 24 months, Incidence of Serious Adverse Events up to 15 months and 6 more. Started Jul 2024; status: recruiting.
02
Drugs
TEV-56278
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06480552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480552.